NR 546 Psychopharmacology Midterm | Chamberlain University Graduate PMHNP Prescribing | Clinical Decision-Making
NR 546 / NR546 Midterm Exam
Psychopharmacology | Latest 2026/2027 | A+ Guarantee |
Tested Questions with Revised Answers
Comprehensive 140-Question Midterm Preparation Guide
Chamberlain University Graduate PMHNP Program | Prescriber-Level Pharmacology | Tested Questions with Revised Answers | 100%
Correct
Instructions: This comprehensive preparation guide consists of 140 multiple-choice questions across nine sections,
aligned with the latest 2026/2027 Chamberlain NR 546 Psychopharmacology midterm course objectives and prescriber
competencies. Each question presents a clinical scenario or direct recall prompt reflecting the prescriber-focused
assessment format—including "Which medication is the BEST initial choice?", "Which monitoring parameter is MOST
important?", and "What should the PMHNP do NEXT?" formats. Select the single best answer (A–D). Correct
responses, marked [CORRECT], and detailed rationales (3–4 sentences) with psychopharmacology reasoning
(mechanism of action, monitoring parameters, interaction risks, prescriber safety considerations) are provided
immediately beneath each question. This A+ Guarantee guide emphasizes high-yield content ensuring complete
coverage of: neuroanatomy, neurotransmission, and psychopharm foundations; pharmacokinetics and
pharmacodynamics (CYP450 interactions, pharmacogenomics); depressive disorders and antidepressant therapy
(SSRIs, SNRIs, bupropion, mirtazapine, TCAs, MAOIs, serotonin syndrome); bipolar disorder and mood stabilizers
(lithium, valproate, lamotrigine, carbamazepine); schizophrenia and antipsychotics (EPS, TD, NMS, clozapine REMS);
anxiety, OCD, and trauma-related disorders (benzodiazepines, buspirone, hydroxyzine); sleep-wake disorders and
sedative-hypnotics (Z-drugs, melatonin agonists, DORAs); ADHD, substance use, and neurocognitive disorders
(stimulants, MAT, cholinesterase inhibitors); and special populations, lifespan, and prescribing safety (pregnancy,
lactation, pediatric, geriatric, Beers Criteria, Black Box Warnings).
Section 1: Neuroanatomy, Neurotransmission, and Psychopharmacology Foundations
(Neurotransmitters, Receptors, Synaptic Transmission, & Blood-Brain Barrier)
This section tests foundational knowledge of neurotransmitter systems, receptor pharmacology, synaptic transmission,
and blood-brain barrier (BBB) penetration—the basis for all psychopharmacologic decision-making in NR 546.
Q1: The dopamine (DA) pathway most associated with positive psychotic symptoms (hallucinations, delusions)
in schizophrenia is the:
A. Nigrostriatal pathway
B. Mesolimbic pathway (hyperactive in schizophrenia, target of antipsychotic blockade) [CORRECT]
C. Mesocortical pathway
D. Tuberoinfundibular pathway
Correct Answer: B
Rationale: Hyperactivity of the mesolimbic dopamine pathway produces positive psychotic symptoms. D2 blockade in this
pathway produces antipsychotic effect. Nigrostriatal (A) blockade causes EPS; mesocortical (C) hypoactivity produces
negative symptoms; tuberoinfundibular (D) blockade causes hyperprolactinemia.
Latest 2026/2027 | Tested Questions with Revised Answers | A+ Guarantee Page 1
,NR 546 Psychopharmacology Midterm | Chamberlain University Graduate PMHNP Prescribing | Clinical Decision-Making
Q2: Antipsychotic-induced extrapyramidal symptoms (EPS) result from dopamine D2 blockade in which
pathway?
A. Mesolimbic
B. Nigrostriatal pathway (D2 blockade causes parkinsonism, dystonia, akathisia) [CORRECT]
C. Mesocortical
D. Tuberoinfundibular
Correct Answer: B
Rationale: D2 blockade in the nigrostriatal pathway produces EPS: parkinsonism, acute dystonia, akathisia, and tardive
dyskinesia. This is why antipsychotics with tighter D2 binding (e.g., haloperidol) cause more EPS than atypicals.
Q3: Antipsychotic-induced hyperprolactinemia results from dopamine blockade in which pathway?
A. Mesolimbic
B. Nigrostriatal
C. Tuberoinfundibular pathway (D2 blockade removes inhibition of prolactin release) [CORRECT]
D. Mesocortical
Correct Answer: C
Rationale: Dopamine normally inhibits prolactin release via the tuberoinfundibular pathway. D2 blockade (e.g.,
risperidone) removes this inhibition, causing hyperprolactinemia (galactorrhea, gynecomastia, amenorrhea, sexual
dysfunction).
Q4: Which neurotransmitter is the primary target of SSRI antidepressants and is implicated in mood, anxiety,
sleep, and appetite regulation?
A. Dopamine
B. Serotonin (5-HT) [CORRECT]
C. Glutamate
D. Acetylcholine
Correct Answer: B
Rationale: SSRIs block the serotonin transporter (SERT), increasing synaptic 5-HT. Serotonin regulates mood, anxiety,
sleep-wake cycles, appetite, and sexual function. This explains SSRI efficacy in depression, OCD, panic, and PTSD, as well
as side effects (GI upset, sexual dysfunction, sleep changes).
Q5: GABA is the primary inhibitory neurotransmitter in the CNS. Which drug class potentiates GABA-A
receptor function and carries dependence risk?
A. SSRIs
B. Benzodiazepines (positive allosteric modulators of GABA-A) [CORRECT]
C. Antipsychotics
D. Stimulants
Correct Answer: B
Rationale: Benzodiazepines bind GABA-A receptors, increasing chloride influx and neuronal hyperpolarization, producing
anxiolysis, sedation, and anticonvulsant effects. Chronic use causes tolerance, dependence, and life-threatening withdrawal
(seizures).
Latest 2026/2027 | Tested Questions with Revised Answers | A+ Guarantee Page 2
,NR 546 Psychopharmacology Midterm | Chamberlain University Graduate PMHNP Prescribing | Clinical Decision-Making
Q6: Glutamate is the primary excitatory neurotransmitter in the CNS. Dysregulation is implicated in which
disorder?
A. Hypertension only
B. Schizophrenia, depression, and neurodegeneration (NMDA hypofunction in schizophrenia; ketamine
targets NMDA) [CORRECT]
C. Asthma
D. Hyperthyroidism
Correct Answer: B
Rationale: Glutamate dysregulation, particularly NMDA receptor hypofunction, is implicated in schizophrenia, depression,
and neurodegeneration. Ketamine (NMDA antagonist) produces rapid antidepressant effects and psychotomimetic
symptoms, supporting glutamate's role.
Q7: Acetylcholine-enhancing medications (cholinesterase inhibitors) are used to treat which condition?
A. Schizophrenia
B. Dementia (Alzheimer's disease) due to cholinergic deficit [CORRECT]
C. Bipolar mania
D. ADHD
Correct Answer: B
Rationale: Donepezil, rivastigmine, and galantamine (cholinesterase inhibitors) increase acetylcholine in the CNS, providing
modest cognitive benefit in Alzheimer's dementia. Memantine (NMDA antagonist) is for moderate-severe disease.
Q8: The blood-brain barrier (BBB) is composed primarily of:
A. Astrocytes only
B. Tight junctions between capillary endothelial cells supported by astrocyte foot processes [CORRECT]
C. Microglia
D. Ependymal cells
Correct Answer: B
Rationale: The BBB is formed by tight junctions between brain capillary endothelial cells, with astrocyte foot processes
providing additional support. Lipid-soluble, small, non-ionized, non-protein-bound drugs cross more easily (e.g., most
psychotropics). Large, water-soluble, or highly protein-bound drugs cross poorly.
Q9: Which drug property BEST predicts ability to cross the blood-brain barrier?
A. High water solubility and high protein binding
B. High lipophilicity, low protein binding, small molecular size, non-ionized state [CORRECT]
C. Large molecular weight
D. High ionization
Correct Answer: B
Rationale: Lipid-soluble (lipophilic), small, non-ionized, and weakly protein-bound drugs cross the BBB most readily. Most
psychotropics (e.g., benzodiazepines, antidepressants, antipsychotics) are lipophilic and cross well. Highly protein-bound or
water-soluble drugs (e.g., penicillin, lithium) cross poorly.
Latest 2026/2027 | Tested Questions with Revised Answers | A+ Guarantee Page 3
, NR 546 Psychopharmacology Midterm | Chamberlain University Graduate PMHNP Prescribing | Clinical Decision-Making
Q10: Why does lithium have a narrow therapeutic index requiring close serum monitoring?
A. It is highly protein-bound and cannot cross the BBB
B. It is a small monovalent cation that distributes in total body water; renal excretion is tightly linked to
sodium handling, creating a narrow margin between therapeutic and toxic levels [CORRECT]
C. It is metabolized by CYP450 enzymes
D. It is a prodrug requiring hepatic activation
Correct Answer: B
Rationale: Lithium is a small monovalent cation distributed in total body water and excreted unchanged by the kidney. It
competes with sodium for reabsorption; sodium-wasting conditions (dehydration, diuretics, ACE inhibitors) increase lithium
retention and toxicity risk. Therapeutic range: 0.6–1.2 mEq/L; toxicity >1.5 mEq/L.
Q11: Which neurotransmitter system is the primary target of methylphenidate and amphetamine stimulants
used in ADHD?
A. Serotonin
B. Dopamine and norepinephrine (reuptake inhibition and release) [CORRECT]
C. GABA
D. Glutamate
Correct Answer: B
Rationale: Stimulants block reuptake and promote release of dopamine and norepinephrine, improving attention, focus, and
impulse control in ADHD. Methylphenidate blocks DAT and NET; amphetamines also promote release from vesicles.
Q12: The mesocortical dopamine pathway is hypoactive in schizophrenia, producing which symptoms?
A. Positive symptoms (hallucinations)
B. Negative and cognitive symptoms (apathy, blunted affect, executive dysfunction) [CORRECT]
C. EPS
D. Hyperprolactinemia
Correct Answer: B
Rationale: Hypoactivity of the mesocortical pathway produces negative and cognitive symptoms of schizophrenia (apathy,
alogia, anhedonia, executive dysfunction). These are harder to treat than positive symptoms; second-generation
antipsychotics (e.g., aripiprazole, cariprazine) may have some benefit.
Q13: Receptor pharmacology: which receptor mechanism produces the antidepressant effect of SSRIs over
weeks despite immediate SERT blockade?
A. Immediate serotonin reuptake blockade
B. Downregulation of postsynaptic 5-HT receptors and adaptive neuroplastic changes over 2–6 weeks
[CORRECT]
C. D2 antagonism
D. GABA-A potentiation
Correct Answer: B
Rationale: Although SSRIs immediately block SERT, therapeutic effect develops over 2–6 weeks due to downregulation of
postsynaptic 5-HT1A receptors, increased BDNF, and neuroplastic adaptations. This delayed onset explains why early SSRI
use may worsen anxiety (5-HT2/5-HT2C stimulation) before improvement.
Latest 2026/2027 | Tested Questions with Revised Answers | A+ Guarantee Page 4
NR 546 / NR546 Midterm Exam
Psychopharmacology | Latest 2026/2027 | A+ Guarantee |
Tested Questions with Revised Answers
Comprehensive 140-Question Midterm Preparation Guide
Chamberlain University Graduate PMHNP Program | Prescriber-Level Pharmacology | Tested Questions with Revised Answers | 100%
Correct
Instructions: This comprehensive preparation guide consists of 140 multiple-choice questions across nine sections,
aligned with the latest 2026/2027 Chamberlain NR 546 Psychopharmacology midterm course objectives and prescriber
competencies. Each question presents a clinical scenario or direct recall prompt reflecting the prescriber-focused
assessment format—including "Which medication is the BEST initial choice?", "Which monitoring parameter is MOST
important?", and "What should the PMHNP do NEXT?" formats. Select the single best answer (A–D). Correct
responses, marked [CORRECT], and detailed rationales (3–4 sentences) with psychopharmacology reasoning
(mechanism of action, monitoring parameters, interaction risks, prescriber safety considerations) are provided
immediately beneath each question. This A+ Guarantee guide emphasizes high-yield content ensuring complete
coverage of: neuroanatomy, neurotransmission, and psychopharm foundations; pharmacokinetics and
pharmacodynamics (CYP450 interactions, pharmacogenomics); depressive disorders and antidepressant therapy
(SSRIs, SNRIs, bupropion, mirtazapine, TCAs, MAOIs, serotonin syndrome); bipolar disorder and mood stabilizers
(lithium, valproate, lamotrigine, carbamazepine); schizophrenia and antipsychotics (EPS, TD, NMS, clozapine REMS);
anxiety, OCD, and trauma-related disorders (benzodiazepines, buspirone, hydroxyzine); sleep-wake disorders and
sedative-hypnotics (Z-drugs, melatonin agonists, DORAs); ADHD, substance use, and neurocognitive disorders
(stimulants, MAT, cholinesterase inhibitors); and special populations, lifespan, and prescribing safety (pregnancy,
lactation, pediatric, geriatric, Beers Criteria, Black Box Warnings).
Section 1: Neuroanatomy, Neurotransmission, and Psychopharmacology Foundations
(Neurotransmitters, Receptors, Synaptic Transmission, & Blood-Brain Barrier)
This section tests foundational knowledge of neurotransmitter systems, receptor pharmacology, synaptic transmission,
and blood-brain barrier (BBB) penetration—the basis for all psychopharmacologic decision-making in NR 546.
Q1: The dopamine (DA) pathway most associated with positive psychotic symptoms (hallucinations, delusions)
in schizophrenia is the:
A. Nigrostriatal pathway
B. Mesolimbic pathway (hyperactive in schizophrenia, target of antipsychotic blockade) [CORRECT]
C. Mesocortical pathway
D. Tuberoinfundibular pathway
Correct Answer: B
Rationale: Hyperactivity of the mesolimbic dopamine pathway produces positive psychotic symptoms. D2 blockade in this
pathway produces antipsychotic effect. Nigrostriatal (A) blockade causes EPS; mesocortical (C) hypoactivity produces
negative symptoms; tuberoinfundibular (D) blockade causes hyperprolactinemia.
Latest 2026/2027 | Tested Questions with Revised Answers | A+ Guarantee Page 1
,NR 546 Psychopharmacology Midterm | Chamberlain University Graduate PMHNP Prescribing | Clinical Decision-Making
Q2: Antipsychotic-induced extrapyramidal symptoms (EPS) result from dopamine D2 blockade in which
pathway?
A. Mesolimbic
B. Nigrostriatal pathway (D2 blockade causes parkinsonism, dystonia, akathisia) [CORRECT]
C. Mesocortical
D. Tuberoinfundibular
Correct Answer: B
Rationale: D2 blockade in the nigrostriatal pathway produces EPS: parkinsonism, acute dystonia, akathisia, and tardive
dyskinesia. This is why antipsychotics with tighter D2 binding (e.g., haloperidol) cause more EPS than atypicals.
Q3: Antipsychotic-induced hyperprolactinemia results from dopamine blockade in which pathway?
A. Mesolimbic
B. Nigrostriatal
C. Tuberoinfundibular pathway (D2 blockade removes inhibition of prolactin release) [CORRECT]
D. Mesocortical
Correct Answer: C
Rationale: Dopamine normally inhibits prolactin release via the tuberoinfundibular pathway. D2 blockade (e.g.,
risperidone) removes this inhibition, causing hyperprolactinemia (galactorrhea, gynecomastia, amenorrhea, sexual
dysfunction).
Q4: Which neurotransmitter is the primary target of SSRI antidepressants and is implicated in mood, anxiety,
sleep, and appetite regulation?
A. Dopamine
B. Serotonin (5-HT) [CORRECT]
C. Glutamate
D. Acetylcholine
Correct Answer: B
Rationale: SSRIs block the serotonin transporter (SERT), increasing synaptic 5-HT. Serotonin regulates mood, anxiety,
sleep-wake cycles, appetite, and sexual function. This explains SSRI efficacy in depression, OCD, panic, and PTSD, as well
as side effects (GI upset, sexual dysfunction, sleep changes).
Q5: GABA is the primary inhibitory neurotransmitter in the CNS. Which drug class potentiates GABA-A
receptor function and carries dependence risk?
A. SSRIs
B. Benzodiazepines (positive allosteric modulators of GABA-A) [CORRECT]
C. Antipsychotics
D. Stimulants
Correct Answer: B
Rationale: Benzodiazepines bind GABA-A receptors, increasing chloride influx and neuronal hyperpolarization, producing
anxiolysis, sedation, and anticonvulsant effects. Chronic use causes tolerance, dependence, and life-threatening withdrawal
(seizures).
Latest 2026/2027 | Tested Questions with Revised Answers | A+ Guarantee Page 2
,NR 546 Psychopharmacology Midterm | Chamberlain University Graduate PMHNP Prescribing | Clinical Decision-Making
Q6: Glutamate is the primary excitatory neurotransmitter in the CNS. Dysregulation is implicated in which
disorder?
A. Hypertension only
B. Schizophrenia, depression, and neurodegeneration (NMDA hypofunction in schizophrenia; ketamine
targets NMDA) [CORRECT]
C. Asthma
D. Hyperthyroidism
Correct Answer: B
Rationale: Glutamate dysregulation, particularly NMDA receptor hypofunction, is implicated in schizophrenia, depression,
and neurodegeneration. Ketamine (NMDA antagonist) produces rapid antidepressant effects and psychotomimetic
symptoms, supporting glutamate's role.
Q7: Acetylcholine-enhancing medications (cholinesterase inhibitors) are used to treat which condition?
A. Schizophrenia
B. Dementia (Alzheimer's disease) due to cholinergic deficit [CORRECT]
C. Bipolar mania
D. ADHD
Correct Answer: B
Rationale: Donepezil, rivastigmine, and galantamine (cholinesterase inhibitors) increase acetylcholine in the CNS, providing
modest cognitive benefit in Alzheimer's dementia. Memantine (NMDA antagonist) is for moderate-severe disease.
Q8: The blood-brain barrier (BBB) is composed primarily of:
A. Astrocytes only
B. Tight junctions between capillary endothelial cells supported by astrocyte foot processes [CORRECT]
C. Microglia
D. Ependymal cells
Correct Answer: B
Rationale: The BBB is formed by tight junctions between brain capillary endothelial cells, with astrocyte foot processes
providing additional support. Lipid-soluble, small, non-ionized, non-protein-bound drugs cross more easily (e.g., most
psychotropics). Large, water-soluble, or highly protein-bound drugs cross poorly.
Q9: Which drug property BEST predicts ability to cross the blood-brain barrier?
A. High water solubility and high protein binding
B. High lipophilicity, low protein binding, small molecular size, non-ionized state [CORRECT]
C. Large molecular weight
D. High ionization
Correct Answer: B
Rationale: Lipid-soluble (lipophilic), small, non-ionized, and weakly protein-bound drugs cross the BBB most readily. Most
psychotropics (e.g., benzodiazepines, antidepressants, antipsychotics) are lipophilic and cross well. Highly protein-bound or
water-soluble drugs (e.g., penicillin, lithium) cross poorly.
Latest 2026/2027 | Tested Questions with Revised Answers | A+ Guarantee Page 3
, NR 546 Psychopharmacology Midterm | Chamberlain University Graduate PMHNP Prescribing | Clinical Decision-Making
Q10: Why does lithium have a narrow therapeutic index requiring close serum monitoring?
A. It is highly protein-bound and cannot cross the BBB
B. It is a small monovalent cation that distributes in total body water; renal excretion is tightly linked to
sodium handling, creating a narrow margin between therapeutic and toxic levels [CORRECT]
C. It is metabolized by CYP450 enzymes
D. It is a prodrug requiring hepatic activation
Correct Answer: B
Rationale: Lithium is a small monovalent cation distributed in total body water and excreted unchanged by the kidney. It
competes with sodium for reabsorption; sodium-wasting conditions (dehydration, diuretics, ACE inhibitors) increase lithium
retention and toxicity risk. Therapeutic range: 0.6–1.2 mEq/L; toxicity >1.5 mEq/L.
Q11: Which neurotransmitter system is the primary target of methylphenidate and amphetamine stimulants
used in ADHD?
A. Serotonin
B. Dopamine and norepinephrine (reuptake inhibition and release) [CORRECT]
C. GABA
D. Glutamate
Correct Answer: B
Rationale: Stimulants block reuptake and promote release of dopamine and norepinephrine, improving attention, focus, and
impulse control in ADHD. Methylphenidate blocks DAT and NET; amphetamines also promote release from vesicles.
Q12: The mesocortical dopamine pathway is hypoactive in schizophrenia, producing which symptoms?
A. Positive symptoms (hallucinations)
B. Negative and cognitive symptoms (apathy, blunted affect, executive dysfunction) [CORRECT]
C. EPS
D. Hyperprolactinemia
Correct Answer: B
Rationale: Hypoactivity of the mesocortical pathway produces negative and cognitive symptoms of schizophrenia (apathy,
alogia, anhedonia, executive dysfunction). These are harder to treat than positive symptoms; second-generation
antipsychotics (e.g., aripiprazole, cariprazine) may have some benefit.
Q13: Receptor pharmacology: which receptor mechanism produces the antidepressant effect of SSRIs over
weeks despite immediate SERT blockade?
A. Immediate serotonin reuptake blockade
B. Downregulation of postsynaptic 5-HT receptors and adaptive neuroplastic changes over 2–6 weeks
[CORRECT]
C. D2 antagonism
D. GABA-A potentiation
Correct Answer: B
Rationale: Although SSRIs immediately block SERT, therapeutic effect develops over 2–6 weeks due to downregulation of
postsynaptic 5-HT1A receptors, increased BDNF, and neuroplastic adaptations. This delayed onset explains why early SSRI
use may worsen anxiety (5-HT2/5-HT2C stimulation) before improvement.
Latest 2026/2027 | Tested Questions with Revised Answers | A+ Guarantee Page 4
